New Delhi: According to sources, Bharat Biotech's Covaxin showed 77.8% efficacy after the pharma regulator's Subject Expert Committee (SEC) reviewed its Phase III study data on Tuesday.
The Hyderabad-based COVID vaccine manufacturing company had submitted data from the Phase III clinical trials of Covaxin to the Drugs Controller General of India (DCGI) over the weekend.
Bharat Biotech's 'pre-submission meeting with the World Health Organization (WHO) will take on Wednesday for the approval of Covaxin.
Covaxin is one of the three vaccines which are currently being used in India. The vaccine's phase III data has been questioned several times. Therefore, the data that determines the vaccine's efficacy is critical.
The company has developed the vaccine in association with the Indian Council of Medical Research (ICMR).